Back to Results

Cellectis SA (CLLS)

Cellectis S.A. is a clinical-stage biotechnology company focused on gene-editing-based therapies. Its research portfolio centers on allogeneic chimeric antigen receptor T-cell product candidates for immuno-oncology, along with gene therapy programs for other therapeutic areas. The company is advancing BALLI-01 to assess lasme-cel in patients with relapsed or refractory acute lymphoblastic leukemia, and NatHaLi-01 to evaluate eti-cel in relapsed or refractory B-cell non-Hodgkin’s lymphoma. Additional programs include ALPHA3 for large B-cell lymphoma, TRAVERSE for advanced or metastatic clear cell renal cell carcinoma, and a melanoma program for unresectable or metastatic disease. Cellectis was founded in 1999 and is headquartered in Paris, France. The listed security is an ADR on NASDAQ representing the company’s common stock.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-CLLS
$3.09
16.2% Upside
Fair
$7.60
185.7% Upside
Bargain
Fair
—
—
—
0.0%
July 30, 2026
-3.0x
3.4x
2.7x
190.4 M
98.533 M
30.2%
64.3%
0.1
—
59.3%
Valuation • Fair Value

Cellectis SA (NASDAQ-CLLS) Fair Value by Valuation Model

Compare the primary fair value estimate for Cellectis SA (NASDAQ-CLLS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$3.09

Estimated upside of 16.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$4.29

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$2.69

Comparable-company valuation reference.

Analyst Price Target

$7.60

Analysts imply upside of 185.7%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Cellectis SA (NASDAQ-CLLS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Cellectis SA (NASDAQ-CLLS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

75.112 M

Current operating scale indicator.

Revenue Forecast

57.929 M

Forward revenue estimate.

EBITDA

-32.749 M

Current operating profitability reference.

EBITDA Forecast

-70.32 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Cellectis SA (NASDAQ-CLLS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cellectis SA (NASDAQ-CLLS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-2.82

No elevated caution signal from this screen.

Altman Z-Score

0.1

Lower score that deserves closer risk review.

FCF / Net Income

59.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cellectis SA (NASDAQ-CLLS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cellectis SA (NASDAQ-CLLS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Cellectis SA (NASDAQ-CLLS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cellectis SA (NASDAQ-CLLS) Stock Forecast & Technical Outlook

Review Cellectis SA (NASDAQ-CLLS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Cellectis SA (NASDAQ-CLLS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cellectis SA (NASDAQ-CLLS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Cellectis SA (NASDAQ-CLLS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Cellectis SA (NASDAQ-CLLS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Cellectis SA (NASDAQ-CLLS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cellectis SA (NASDAQ-CLLS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Cellectis SA (NASDAQ-CLLS) has a Buy consensus, with 2 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 1
Sell 0
FAQ • Fast Investor Answers

Cellectis SA (NASDAQ-CLLS) Stock FAQ

Quick answers about Cellectis SA (NASDAQ-CLLS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$3.09
Estimated upside 16.2%
Valuation Rating
Undervalued
Estimated upside of 16.2%
Analyst Target
$7.60
Implied upside 185.7%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Cellectis SA (NASDAQ-CLLS) is $3.09. This implies an estimated upside of 16.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 16.2% versus the current market price.

The available analyst price target for Cellectis SA (NASDAQ-CLLS) is $7.60. The analyst target implies estimated upside of 185.7%.

The current financial health read for Cellectis SA (NASDAQ-CLLS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cellectis SA (NASDAQ-CLLS) is July 30, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Cellectis SA (NASDAQ-CLLS) is -3.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Cellectis SA is 190.4 M.

The current enterprise value listed for Cellectis SA is 98.533 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cellectis SA is NASDAQ-CLLS, and the stock is listed on NASDAQ.

Cellectis SA (NASDAQ-CLLS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Cellectis SA is 30.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cellectis SA is 64.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)